CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb. 15, 2006--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY): Company Enters Clinical Stage and Forms Significant Pharmaceutical Alliances. Maintains Leadership Position for RNAi Therapeutics in Science, Product Pipeline, Intellectual Property, and Business Execution. Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, today reported its consolidated financial results for the quarter and year ended December 31, 2005, guidance and goals for 2006, and company highlights.
